Angelicin (Synonyms: 异补骨脂素; Isopsoralen)

目录号: HY-N0763 纯度: 99.86%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

异补骨脂素 (Angelicin) 是一种天然的三环芳烃化合物，结构上跟补骨脂素有关，具有抗癌、抗炎、抗病毒等活性。具有细胞毒性，IC50：49.56 μM；抑制MHV-68，IC50: 5.39 μg/ml (28.95 μM)。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Angelicin Chemical Structure

CAS No. : 523-50-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
25 mg	￥500	In-stock
50 mg	￥800	In-stock
100 mg		询价
200 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Other Forms of Angelicin:

Angelicin (Standard) 询价

MCE 顾客使用本产品发表的 8 篇科研文献

Angelicin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Angelicin, a furocoumarin naturally occurring tricyclic aromatic compound, structurally related to psoralens, is reported to have anti-cancer, antiviral, anti-inflammatory activity. IC50 value: 49.56 μM (cellular cytotoxicity); 5.39 μg/ml (28.95 μM) (against MHV-68) Target: In vitro: In human SH-SY5Y neuroblastoma cells, angelicin increased cellular cytotoxicity in a dose- and time-dependent manner with IC50 of 49.56 μM at 48 h of incubation. Angelicin dose-dependently downregulated the expression of anti-apoptotic proteins including Bcl-2, Bcl-xL, and Mcl-1; Angelicin-induced apoptosis is mediated primarily through the intrinsic caspase-mediated pathway[1]. Angelicin efficiently inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced lytic replication of human gammaherpresviruses in both EBV- and KSHV-infected cells [2]. Angelicin was potentially advantageous to prevent inflammatory diseases by inhibiting NF-κB and MAPK pathways [3]. In vivo:

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 10 μM Compound: 21	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25710081]
HL-60	IC₅₀	0.9 μM Compound: Ang	Phototoxicity in 3.75 J/cm'2 UV-A irradiated human HL60 cells after 72 hrs by MTT assay Phototoxicity in 3.75 J/cm'2 UV-A irradiated human HL60 cells after 72 hrs by MTT assay	[PMID: 21397509]
HL-60	IC₅₀	0.9 μM Compound: 2, ANG	Photocytotoxicity against human HL-60 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human HL-60 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
HL-60	IC₅₀	1.2 μM Compound: Ang	Phototoxicity in 2.5 J/cm'2 UV-A irradiated human HL60 cells after 72 hrs by MTT assay Phototoxicity in 2.5 J/cm'2 UV-A irradiated human HL60 cells after 72 hrs by MTT assay	[PMID: 21397509]
HL-60	IC₅₀	1.2 μM Compound: 2, ANG	Photocytotoxicity against human HL-60 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human HL-60 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
HL-60	GI₅₀	1.2 μM Compound: Ang	Photocytotoxicity against human HL60 cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay Photocytotoxicity against human HL60 cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay	[PMID: 26295175]
HT-1080	IC₅₀	15.7 μM Compound: 2, ANG	Photocytotoxicity against human HT1080 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human HT1080 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
HT-1080	IC₅₀	15.7 μM Compound: Angelicin	Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line	[PMID: 12873520]
HT-1080	IC₅₀	2.5 μM Compound: Angelicin	Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line	[PMID: 12873520]
HT-1080	IC₅₀	2.6 μM Compound: 2, ANG	Photocytotoxicity against human HT1080 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human HT1080 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
HT-1080	IC₅₀	2.6 μM Compound: Angelicin	Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line	[PMID: 12873520]
Jurkat	IC₅₀	> 20 μM Compound: 2, Ang	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 19230658]
Jurkat	IC₅₀	0.9 μM Compound: Ang	Phototoxicity in 3.75 J/cm'2 UV-A irradiated human Jurkat cells after 72 hrs by MTT assay Phototoxicity in 3.75 J/cm'2 UV-A irradiated human Jurkat cells after 72 hrs by MTT assay	[PMID: 21397509]
Jurkat	IC₅₀	0.9 μM Compound: Ang	Phototoxicity against human Jurkat cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay Phototoxicity against human Jurkat cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay	[PMID: 20627596]
Jurkat	IC₅₀	0.9 μM Compound: 2, ANG	Photocytotoxicity against human JURKAT cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human JURKAT cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
Jurkat	IC₅₀	0.9 μM Compound: 2, Ang	Phototoxicity against human Jurkat cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay Phototoxicity against human Jurkat cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay	[PMID: 19230658]
Jurkat	IC₅₀	1 μM Compound: Ang	Phototoxicity in 2.5 J/cm'2 UV-A irradiated human Jurkat cells after 72 hrs by MTT assay Phototoxicity in 2.5 J/cm'2 UV-A irradiated human Jurkat cells after 72 hrs by MTT assay	[PMID: 21397509]
Jurkat	IC₅₀	1 μM Compound: Ang	Phototoxicity against human Jurkat cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay Phototoxicity against human Jurkat cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay	[PMID: 20627596]
Jurkat	GI₅₀	1 μM Compound: Ang	Photocytotoxicity against human Jurkat cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay Photocytotoxicity against human Jurkat cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay	[PMID: 26295175]
K562	IC₅₀	> 10 μM Compound: 21	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 25710081]
K562	IC₅₀	> 20 μM Compound: 2, Ang	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 19230658]
K562	IC₅₀	1 μM Compound: Ang	Phototoxicity against human K562 cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay Phototoxicity against human K562 cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay	[PMID: 20627596]
K562	IC₅₀	1.2 μM Compound: Ang	Phototoxicity against human K562 cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay Phototoxicity against human K562 cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay	[PMID: 20627596]
LoVo	IC₅₀	> 20 μM Compound: 2, Ang	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 19230658]
LoVo	IC₅₀	0.9 μM Compound: 2, ANG	Photocytotoxicity against human LoVo cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human LoVo cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
LoVo	IC₅₀	0.9 μM Compound: 2, Ang	Phototoxicity against human LoVo cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay Phototoxicity against human LoVo cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay	[PMID: 19230658]
LoVo	IC₅₀	1.1 μM Compound: Ang	Phototoxicity in 3.75 J/cm'2 UV-A irradiated human LoVo cells after 72 hrs by MTT assay Phototoxicity in 3.75 J/cm'2 UV-A irradiated human LoVo cells after 72 hrs by MTT assay	[PMID: 21397509]
LoVo	GI₅₀	1.11 μM Compound: Ang	Photocytotoxicity against human LoVo cells assessed as growth inhibition at 3.75 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay Photocytotoxicity against human LoVo cells assessed as growth inhibition at 3.75 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay	[PMID: 26295175]
LoVo	IC₅₀	1.5 μM Compound: Ang	Phototoxicity against human LoVo cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay Phototoxicity against human LoVo cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay	[PMID: 20627596]
LoVo	IC₅₀	1.6 μM Compound: 2, ANG	Photocytotoxicity against human LoVo cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human LoVo cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
LoVo	IC₅₀	1.6 μM Compound: 2, Ang	Phototoxicity against human LoVo cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay Phototoxicity against human LoVo cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay	[PMID: 19230658]
LoVo	IC₅₀	3.6 μM Compound: Ang	Phototoxicity against human LoVo cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay Phototoxicity against human LoVo cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay	[PMID: 20627596]
LoVo	IC₅₀	4 μM Compound: Ang	Phototoxicity in 2.5 J/cm'2 UV-A irradiated human LoVo cells after 72 hrs by MTT assay Phototoxicity in 2.5 J/cm'2 UV-A irradiated human LoVo cells after 72 hrs by MTT assay	[PMID: 21397509]
LoVo	GI₅₀	4 μM Compound: Ang	Photocytotoxicity against human LoVo cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay Photocytotoxicity against human LoVo cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay	[PMID: 26295175]
MCF7	IC₅₀	1.5 μM Compound: Ang	Phototoxicity in 3.75 J/cm'2 UV-A irradiated human MCF7 cells after 72 hrs by MTT assay Phototoxicity in 3.75 J/cm'2 UV-A irradiated human MCF7 cells after 72 hrs by MTT assay	[PMID: 21397509]
MCF7	IC₅₀	1.5 μM Compound: Ang	Phototoxicity against human MCF7 cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay Phototoxicity against human MCF7 cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay	[PMID: 20627596]
MCF7	GI₅₀	1.5 μM Compound: Ang	Photocytotoxicity against human MCF7 cells assessed as growth inhibition at 3.75 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay Photocytotoxicity against human MCF7 cells assessed as growth inhibition at 3.75 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay	[PMID: 26295175]
MCF7	IC₅₀	4.4 μM Compound: Ang	Phototoxicity in 2.5 J/cm'2 UV-A irradiated human MCF7 cells after 72 hrs by MTT assay Phototoxicity in 2.5 J/cm'2 UV-A irradiated human MCF7 cells after 72 hrs by MTT assay	[PMID: 21397509]
MCF7	IC₅₀	4.4 μM Compound: Ang	Phototoxicity against human MCF7 cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay Phototoxicity against human MCF7 cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay	[PMID: 20627596]
MCF7	GI₅₀	4.42 μM Compound: Ang	Photocytotoxicity against human MCF7 cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay Photocytotoxicity against human MCF7 cells assessed as growth inhibition at 2.5 J/cm'2 irradiation for 30 mins followed by drug treated for 72 hrs by MTT assay	[PMID: 26295175]
NCTC-2544	IC₅₀	> 20 μM Compound: 2, Ang	Cytotoxicity against human NCTC-2544 cells after 72 hrs by MTT assay Cytotoxicity against human NCTC-2544 cells after 72 hrs by MTT assay	[PMID: 19230658]
NCTC-2544	IC₅₀	0.9 μM Compound: Ang	Phototoxicity in 3.75 J/cm'2 UV-A irradiated human NCTC-2544 cells after 72 hrs by MTT assay Phototoxicity in 3.75 J/cm'2 UV-A irradiated human NCTC-2544 cells after 72 hrs by MTT assay	[PMID: 21397509]
NCTC-2544	IC₅₀	0.9 μM Compound: Ang	Phototoxicity against human sNCTC-2544 cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay Phototoxicity against human sNCTC-2544 cells irradiated with 3.75 J/cm'2 after 72 hrs by MTT assay	[PMID: 20627596]
NCTC-2544	IC₅₀	1.5 μM Compound: 2, ANG	Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
NCTC-2544	IC₅₀	4.2 μM Compound: Ang	Phototoxicity in 2.5 J/cm'2 UV-A irradiated human NCTC-2544 cells after 72 hrs by MTT assay Phototoxicity in 2.5 J/cm'2 UV-A irradiated human NCTC-2544 cells after 72 hrs by MTT assay	[PMID: 21397509]
NCTC-2544	IC₅₀	4.2 μM Compound: Ang	Phototoxicity against human sNCTC-2544 cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay Phototoxicity against human sNCTC-2544 cells irradiated with 2.5 J/cm'2 after 72 hrs by MTT assay	[PMID: 20627596]
NCTC-2544	IC₅₀	4.2 μM Compound: 2, ANG	Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
NCTC-2544	IC₅₀	4.2 μM Compound: 2, Ang	Phototoxicity against human NCTC-2544 cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay Phototoxicity against human NCTC-2544 cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay	[PMID: 19230658]

分子量

186.16

Formula

C₁₁H₆O₃

CAS 号

523-50-2

性状

固体

颜色

White to off-white

中文名称

异补骨脂素；异香柠檬烯；异佛手柑内酯；异补骨酯素；当归素

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 33.33 mg/mL (179.04 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	5.3717 mL	26.8586 mL	53.7172 mL
5 mM	1.0743 mL	5.3717 mL	10.7434 mL
10 mM	0.5372 mL	2.6859 mL	5.3717 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (13.43 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (13.43 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.86%

选择批次：

Data Sheet (626 KB) SDS (393 KB)

COA (290 KB) HNMR (306 KB) LCMS (120 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Md. Ataur Rahman, Angelicin induces apoptosis through intrinsic caspase-dependent pathway in human SH-SY5Y neuroblastoma cells. Molecular and Cellular Biochemistry October 2012, Volume 369, Issue 1-2, pp 95-104

[2]. Hye-Jeong Cho, et al. Antiviral activity of angelicin against gammaherpesviruses. Antiviral Research Volume 100, Issue 1, October 2013, Pages 75–83

[3]. Fang Liu, et al. Angelicin regulates LPS-induced inflammation via inhibiting MAPK/NF-κB pathways. Journal of Surgical Research Volume 185, Issue 1, November 2013, Pages 300–309

Angelicin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.3717 mL	26.8586 mL	53.7172 mL	134.2931 mL
	5 mM	1.0743 mL	5.3717 mL	10.7434 mL	26.8586 mL
	10 mM	0.5372 mL	2.6859 mL	5.3717 mL	13.4293 mL
	15 mM	0.3581 mL	1.7906 mL	3.5811 mL	8.9529 mL
	20 mM	0.2686 mL	1.3429 mL	2.6859 mL	6.7147 mL
	25 mM	0.2149 mL	1.0743 mL	2.1487 mL	5.3717 mL
	30 mM	0.1791 mL	0.8953 mL	1.7906 mL	4.4764 mL
	40 mM	0.1343 mL	0.6715 mL	1.3429 mL	3.3573 mL
	50 mM	0.1074 mL	0.5372 mL	1.0743 mL	2.6859 mL
	60 mM	0.0895 mL	0.4476 mL	0.8953 mL	2.2382 mL
	80 mM	0.0671 mL	0.3357 mL	0.6715 mL	1.6787 mL
	100 mM	0.0537 mL	0.2686 mL	0.5372 mL	1.3429 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Angelicin523-50-2Isopsoralen异补骨脂素异香柠檬烯异佛手柑内酯异补骨酯素当归素ApoptosisVirus ProteaseInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Angelicin (Synonyms: 异补骨脂素; Isopsoralen)

Other Forms of Angelicin:

MCE 顾客使用本产品发表的 8 篇科研文献

Angelicin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Angelicin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Angelicin (Synonyms: 异补骨脂素; Isopsoralen)

Other Forms of Angelicin:

Angelicin 相关抗体

MCE 顾客使用本产品发表的 8 篇科研文献

Angelicin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Angelicin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z